Zhejiang Garden Bio‑Chemical Q3 2026: Flat Stock, Rising Costs, and Delayed Vitamin Projects
Explore Zhejiang Garden Bio‑Chemical’s Q3 2026 earnings: revenue grew but profits fell amid rising raw‑material costs and delayed vitamin‑B6 projects.
- ZHEJIANG GARDEN BIO-CHEMIC
- China
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read